Anti-JNK2 Magnetic Beads Immunoprecipitation (IP) Kit

Price:
Size:
Number:

Anti-JNK2 Magnetic Beads-IP Kit Product Components

Components Storage
Anti-JNK2 Magnetic Beads1,3 2-8℃ for 12 months
NP40 Cell Lysis Buffer2 -20℃ for 12 months
5×TBST(pH7.4)  
1×TBST(pH7.4)  
ddH2O  
Alkaline Elution Buffer 2-8℃ for 12 months
Acidity Elution Buffer 2-8℃ for 12 months
Neutralization Buffer 2-8℃ for 12 months

【1】The IP KIT contains anti-JNK2 magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).

【2】Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.

【3】Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.

Anti-JNK2 Magnetic Beads-IP Kit Product Description

The Anti-JNK2 magnetic Beads, conjugated with Anti-JNK2 antibody, are used for immuneprecipitation (IP) of JNK2 proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing JNK2 proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound JNK2 proteins are dissociated from the magnetic beads using an elution buffer.

Anti-JNK2 Magnetic Beads-IP Kit Antibody Information

Antibody
Anti-JNK2 Antibody(10745-R004)
Immunogen
Recombinant Human JNK2 / MAPK9 Protein (Catalog#10745-H08B)
Species Reactivity
Human JNK2 / MAPK9
Source
Monoclonal Human Rabbit IgG
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human JNK2 / MAPK9 (rh JNK2 / MAPK9; Catalog#10745-H08B; NP_002743.3; Met 1-Arg 424).
Applications
Immunoprecipitation (IP), Minimum Protein Purification

Anti-JNK2 Magnetic Beads Immunoprecipitation (IP) Kit: Alternative Names

Anti-JNK-55ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-JNK2ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-JNK2AALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-JNK2ALPHAALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-JNK2BALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-JNK2BETAALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-p54aALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-p54aSAPKALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-PRKM9ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-SAPKALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-SAPK1aALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit

JNK2 Background Information

Mitogen-activated protein kinase 9 (MAPK9), also well known as c-Jun N-terminal kinase (JNK2), is a member of MAP kinase subfamily belonging to the protein kinase superfamily. MAPK9 responds to activation by environmental stress and pro-inflammatory cytokines by phosphorylating a number of transcription factors, such as c-Jun and ATF2. The crystal structure of human JNK2 complexed with an indazole inhibitor by applying a high-throughput protein engineering and surface-site mutagenesis approach. A novel conformation of the activation loop is observed, which is not compatible with its phosphorylation by upstream kinases. This activation inhibitory conformation of JNK2 is stabilized by the MAP kinase insert that interacts with the activation loop in an induced-fit manner. It suggest that the MAP kinase insert of JNK2 plays a role in the regulation of JNK2 activation, possibly by interacting with intracellular binding partners. JNK2 deficiency leads to reduced c-Jun degradation, thereby augmenting c-Jun levels and cellular proliferation, and suggests that JNK2 is a negative regulator of cellular proliferation in multiple cell types. JNK2 prevents replicative stress by coordinating cell cycle progression and DNA damage repair mechanisms. JNK2 blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells. JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response. Lack of JNK2 expression was associated with higher tumor aneuploidy and reduced DNA damage response. Additionally,the JNK2 protein could be a novel therapeutic target in dry eye disease, and may provide a novel target for prevention of vascular disease and atherosclerosis.
Full Name
mitogen-activated protein kinase 9
Research Areas
References
  • Sabapathy K, et al. (2004) JNK2: a negative regulator of cellular proliferation. Cell Cycle. 3(12): 1520-3.
  • Tao J, et al. (2007) JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Eur J Immunol. 37(3): 818-29.
  • Shaw D, et al. (2008) The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity. J Mol Biol. 383(4): 885-93.
  • Osto E, et al. (2008) c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. 118(20): 2073-80.
  • De Paiva CS, et al. (2009) Essential role for c-Jun N-terminal kinase 2 in corneal epithelial response to desiccating stress. Arch Ophthalmol. 127(12): 1625-31.
  • Chen P, et al. (2010) Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One. 5(5): e10443.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait